mefenamic acid
Trade name: ponstel
Approved
Mar 28, 1967
Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is used for the treatment of mild to moderate pain, including menstrual pain, inflammation, and fever. Clinical use of mefenamic acid has generally declined in an era where other NSAID use has flourished. While having modes of action and general toxicities similar to other NSAIDs, mefenamic acid, as a member of the fenamates, nevertheless possesses some unique in vitro effects that have the potential to distinguish this agent from others. Use of this drug remains relevant for pain syndromes and some gynecological disorders, albeit with considerable competition from other NSAIDs. New basic science has considerably improved the understanding of the biochemistry of mefenamic acid. As well as maintaining its use in traditional settings, there is a tremendous potential for expanding the application of mefenamic acid to niche roles. Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. Mefenamic acid concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because mefenamic acid is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. — NCATS
Clinical trial activity
13 trials · 16 clinical orgs · 12 marketing orgs
Earliest trial started Jan 1, 1998 (NCT02183025)
Timeline
1960s
- Mar 28, 1967
Parke-Davis — Earliest FDA Approval
- Mar 28, 1967
Shionogi — NDA Secondary Org
- Mar 28, 1967
Parke-Davis — NDA Organization
- Mar 28, 1967
Avion Pharmaceuticals — Marketing Organization
- Mar 28, 1967
Avion Pharmaceuticals — NDA Secondary Org
1990s
- Jan 1, 1998
Earliest Phase 2 Sponsor(trial)
2010s
- Nov 19, 2010
Micro Labs Ltd India — Marketing Organization
- Jul 22, 2011
Lupin — Marketing Organization
- Feb 5, 2013
Esteve Labs — Marketing Organization
- Feb 5, 2013
Nostrum Laboratories — Marketing Organization
- Feb 5, 2013
MPP PHARMA — Marketing Organization
- Jun 2, 2014
Belcher Pharmaceuticals — Marketing Organization
- Jun 2, 2014
AJENAT PHARMS — Marketing Organization
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
2020s
- Sep 18, 2020
Strides Pharma Science — Marketing Organization
- Sep 18, 2020
Chartwell Pharmaceuticals — Marketing Organization
Indications
Mechanism of action
- CyclooxygenaseANTAGONIST
Cyclooxygenase antagonist
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Approval history
- approvedMar 28, 1967
Chemistry & pharmacology
SMILES
CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1- Mol. weight
- 241.2851 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaMefenamic acid ↗
- NCATS367589PJ2C ↗
- ChEMBLCHEMBL686 ↗
Also known as
- acide méfénamique
- acide méfénamique
- acido mefenamico
- acido mefenamico
- acidum mefenamicum
- acidum mefenamicum
- ayurved siriraj prasaplai
- ci-473
- ci-473
- cn 35355
- cn 35355
- cn-35355
- cn-35355
- contraflam
- contraflam
- dysman-250
- dysman-500
- inf 3355
- inf 3355
- inf-3355
- inf-3355
- mefananmic acid
- mefenacid
- mefenamate
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenamic acid
- mefenaminsaeure
- mefenaminsaeure
- mefenaminsäure
- mefenaminsäure
- meflam 250
- meflam 500
- mendys
- mephenamic acid
- n-(2,3-xylyl)-2-aminobenzoic acid
- n-(2,3-xylyl)-2-aminobenzoic acid
- n-2,3-xylylanthranilic acid
- n-2,3-xylylanthranilic acid
- opustan 250
- opustan 500
- ponstan
- ponstan
- ponstan fte
- ponstel
- ponstel
- ponstel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06277609 | Phase 1 | Feb 27, 2024 | Lundbeck |
| NCT05181007 | Phase 1 | Dec 17, 2021 | Haisco Pharmaceutical |
| NCT05064449 | Phase 1 | Oct 14, 2021 | Takeda |
| NCT04902105 | Phase 1 | May 13, 2021 | Emalex Biosciences, Nuventra Pharma Sciences, Inc., Syneos Health |
| NCT03323671 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2017 | Mansoura University |
| NCT03070678 | Phase 1 | Mar 14, 2017 | Sanofi |
| NCT02943655 | Phase 3 | Nov 1, 2016 | Assiut University |
| NCT01942122 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2015 | Dexa Medica Group, University of Indonesia |
| NCT02417337 | Phase 2 | Aug 1, 2012 | University of Khartoum |
| NCT01598012 | Phase 4 | Dec 1, 2011 | Mahidol University |
| NCT01295294 | Phase 4 | Mar 1, 2011 | Bayer |
| NCT01060696 | N/A | Jan 1, 2009 | Mahidol University, Siriraj Hospital |
| NCT02183025 | Phase 2 | Jan 1, 1998 | Boehringer Ingelheim |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mahidol University | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Bayer | For profit | 1 | 1 | 1 | 2011 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 1998 |
| Dexa Medica Group | For profit | 1 | 1 | 1 | 2015 |
| Emalex Biosciences | For profit | 1 | 1 | 1 | 2021 |
| Haisco Pharmaceutical | For profit | 1 | 1 | 1 | 2021 |
| Lundbeck | For profit | 1 | 1 | 1 | 2024 |
| Mansoura University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Nuventra Pharma Sciences, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Sanofi | For profit | 1 | 1 | 1 | 2017 |
| Siriraj Hospital | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Syneos Health | For profit | 1 | 0 | 1 | 2021 |
| Takeda | For profit | 1 | 1 | 1 | 2021 |
| University of Indonesia | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Khartoum | Academic/Hospital | 1 | 1 | 1 | 2012 |
Marketing (15)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AJENAT PHARMS | For profit | MKTG | Jun 2, 2014 |
| Avion Pharmaceuticals | For profit | MKTG | Mar 28, 1967 |
| Avion Pharmaceuticals | For profit | NDA2 | Mar 28, 1967 |
| Belcher Pharmaceuticals | For profit | MKTG | Jun 2, 2014 |
| Belcher Pharmaceuticals | For profit | SYN | Jun 2, 2014 |
| Chartwell Pharmaceuticals | For profit | MKTG | Sep 18, 2020 |
| Esteve Labs | For profit | SYN | Feb 5, 2013 |
| Esteve Labs | For profit | MKTG | Feb 5, 2013 |
| Lupin | For profit | MKTG | Jul 22, 2011 |
| MPP PHARMA | For profit | MKTG | Feb 5, 2013 |
| Micro Labs Ltd India | For profit | MKTG | Nov 19, 2010 |
| Nostrum Laboratories | For profit | MKTG | Feb 5, 2013 |
| Parke-Davis | For profit | NDA | Mar 28, 1967 |
| Shionogi | For profit | NDA2 | Mar 28, 1967 |
| Strides Pharma Science | For profit | MKTG | Sep 18, 2020 |